Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAS trial of letrozole + hCG for anabolic steroid-induced male hypogonadism
2020-002612-52Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hypoandrogenism (TD) comparing Letrozole + chorionic gonadotropin with Placebo (2 arms). Primary endpoint: Change in plasma total testosterone concentration after 24 weeks from baseline. Started Nov 2020; status: terminated.
02
Drugs
letrozolehuman chorionic gonadotropin
03
Conditions
Hypoandrogenism (TD)
Beyond the preview
Go deeper on 2020-002612-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002612-52.